Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jul 18, 2024
Data Byte

New AMD data showcase the promise and high bar for vectorized biologics

Two gene therapies reduced the need for VEGF injections, but just the suggestion of imperfect safety sent shares of one company tumbling 
BioCentury | Aug 19, 2022
Finance

Carlyle, Abingworth back Opthea’s AMD ambitions in largest-ever Australian deal

First risk-sharing investment since VC’s takeout will position strategic entity Launch to advise Australian biotech as it navigates Phase III with up to $260M
BioCentury | Feb 28, 2017
Distillery Therapeutics

Renal

BioCentury | Jun 4, 2015
Distillery Therapeutics

Therapeutics: Vascular endothelial growth factor B (VEGF-B)

Items per page:
1 - 8 of 8